This is a group of inherited eye conditions that cause vision loss. It happens because the optic nerve, which connects the eye to the brain, doesn't work properly. It's passed down in families and can affect vision gradually.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Hereditary optic atrophy is a group of inherited conditions in which the optic nerve, the cable of nerve fibers that carries signals from each eye to the brain, gradually loses its working cells. As those cells die, the nerve thins and looks pale to an eye doctor, and vision becomes less sharp. Central vision, the part used for reading, driving and recognizing faces, is usually hit hardest, and color vision is often affected too. Glasses cannot correct this kind of vision loss, because the problem lies in the nerve rather than in how the eye focuses light. The two most common forms behave quite differently. Leber hereditary optic neuropathy (LHON) usually starts in the teens or twenties with fairly sudden, painless clouding of central vision in one eye, followed by the other eye within weeks or months. Dominant optic atrophy (DOA) usually begins in childhood and worsens slowly, often so gradually that people cannot say when it started. Some people with either form also have problems outside the eye, such as hearing loss, which is why these conditions are sometimes described as LHON plus or DOA plus.
Both main forms are caused by changes in genes that keep mitochondria, the energy-producing parts of cells, working properly. The cells that make up the optic nerve use a great deal of energy, so they are especially vulnerable when that supply falters. The forms are passed down in different ways. LHON is caused by a change in mitochondrial DNA, which children inherit only from their mother. A woman who carries the change passes it to all of her children, while a man who carries it does not pass it on. Many carriers never lose vision: more than half of male carriers and more than 85 percent of female carriers remain unaffected, and men are affected far more often than women. Smoking and heavy alcohol use are recognized risk factors for vision loss in carriers, which is why carriers are advised to avoid both. DOA is most often caused by a change in a gene called OPA1 and is inherited in an autosomal dominant pattern, meaning one altered copy is enough and each child of an affected parent has a one in two chance of inheriting it. Severity can vary widely even within the same family. A family history makes these conditions more likely, but it is not always present. LHON can appear in families with no known vision loss, and DOA can arise from a new genetic change.
Diagnosis usually starts with an eye specialist, often a neuro-ophthalmologist, who measures sharpness of vision, color vision and the visual field (a map of what each eye can see, which in these conditions typically shows a blind spot in the center). The doctor looks at the optic nerve at the back of the eye, where atrophy shows up as paleness. Optical coherence tomography (OCT), a painless scan that measures the thickness of the nerve fiber layer, helps show the pattern and extent of damage over time. Many other problems can damage the optic nerve, including glaucoma, inflammation such as optic neuritis, pressure from a growth, certain toxins and nutritional deficiencies. Depending on the picture, blood tests or brain imaging may be used to rule these out. A careful family history is also important, especially of vision loss on the mother's side. Genetic testing from a blood sample confirms the diagnosis and the exact form. For LHON, three common mitochondrial DNA changes account for about 90 percent of cases, so testing is often quick. DOA can be caused by many different changes, so broader gene testing is usually needed. Genetic counseling helps families understand what a result means for relatives, including people who carry a gene change but have no symptoms.
There is no treatment that restores a damaged optic nerve, but some options can help people keep or regain usable vision, and practical support makes a large difference in daily life. For LHON, the most studied medicine is idebenone, a synthetic compound related to coenzyme Q10 that is thought to help nerve cells make energy despite the faulty mitochondria. It is approved in the European Union for LHON. Studies suggest it is more likely to help when started early, ideally within the first year of vision loss, and experts recommend taking it for at least a year to judge whether it is working. The evidence is limited: the main randomized trial did not meet its primary goal, though later studies showed more people regaining or keeping useful vision than expected without treatment, and response varies with the specific gene change. It is not recommended for carriers who have not lost vision. Gene therapy injected into the eye has been tested in trials for the most common LHON gene change, with some encouraging results, but it remains under study. For DOA, there is no established medical treatment. Idebenone has been tried in small studies, but the evidence is too limited to know whether it helps. For both forms, avoiding smoking and limiting alcohol is advised. Vision rehabilitation teaches ways to make the most of remaining sight, using magnifiers, screen readers, better lighting and other aids. Low vision services, school or workplace accommodations and mobility training can help people keep studying, working and living independently.
The course depends on the form. In LHON, vision usually drops over several weeks and then stabilizes, typically leaving a large blind spot in the center while side vision is kept. Most people are left with significant, lasting vision loss, but some regain part of their central vision months or years later. This is more likely with one particular gene change (listed on genetic test reports as m.14484T>C) and when vision loss begins at a younger age. In DOA, vision loss is usually milder and slower, may stay stable for long stretches, and does not recover on its own. Many people with DOA keep enough vision for many everyday tasks, though driving may not be possible for some. Because central vision is affected, reading, recognizing faces and driving are often the hardest tasks, while getting around is usually easier thanks to preserved side vision. Adjusting to vision loss, particularly when it arrives suddenly in a young adult with LHON, can be emotionally hard, and support from low vision specialists and peer groups can help. Follow-up usually includes regular eye exams to track vision and the optic nerve. People with LHON are advised to have a heart evaluation, because some have heart rhythm or heart muscle problems even without symptoms. People with DOA are often advised to have regular hearing checks, since about one in five develop problems beyond the eye, such as hearing loss, nerve or muscle problems, or difficulty with balance.
Arrange an eye exam if you notice gradual blurring, difficulty telling colors apart, or trouble reading or recognizing faces, especially if relatives have unexplained vision loss. If you know you carry an LHON gene change, ask about a plan for monitoring and genetic counseling for your family. If you have LHON, palpitations or fainting need prompt assessment by your primary doctor or a heart specialist rather than your eye doctor, and fainting should be checked the same day, because LHON can come with heart rhythm problems. If you have DOA and develop hearing loss, numbness, unsteadiness or drooping eyelids, tell your primary doctor or the specialist who coordinates your care, so these problems can be assessed. Sudden loss or clouding of vision in one or both eyes, or a new blind spot in the center of vision, needs emergency eye care right away. Many conditions can cause this, some of them treatable, and in LHON earlier assessment means treatment can start sooner.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Hereditary Optic Atrophy is like, what's helped you, or ask the community a question.